title: Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers.
abstract: Metoclopramide, a drug used for the relief of nausea and emesis, is currently under development as a radio- and chemosensitizing agent. Its usefulness in high doses, however, is limited by its central nervous system side effects. Neu-metoclopramide (Neu-Sensamide), a novel, concentrated, phosphate-buffered, pH-adjusted (pH = 6.5-7.0) formulation of metoclopramide, has been shown to have an improved side-effect profile in animal studies. The present double-blind, four-way crossover study compared the central nervous system effects and pharmacokinetics of neu-metoclopramide (intravenously and intramuscularly at 1.8 mg/kg) with intravenous metoclopramide and intramuscular placebo in 19 healthy male volunteers. Eight participants withdrew from the study, one because of noncompliance and seven because of adverse events. A total of 28 central nervous system events were observed with intravenous metoclopramide administration, whereas 16, 15, and 6 such events were attributed to intravenous neu-metoclopramide, intramuscular neu-metoclopramide, and placebo, respectively. Extra-pyramidal effects occurred on 10 occasions: 7 after intravenous metoclopramide, 2 after intravenous neu-metoclopramide, and 1 after intramuscular neu-metoclopramide. No significant differences were observed in the pharmacokinetic profiles of the three formulations of metoclopramide. It may be speculated, therefore, that the molecular conformational changes inherent to neu-metoclopramide result in a reduced side-effect profile compared with conventional metoclopramide formulations.
authors.affiliation: Cato Research Israel, Tel-Aviv, Israel.
authors.forename: H H
authors.initials: HH
authors.lastname: Rotmensch
authors.forename: G P
authors.initials: GP
authors.lastname: Mould
authors.forename: J A
authors.initials: JA
authors.lastname: Sutton
authors.forename: S
authors.initials: S
authors.lastname: Kilminster
authors.forename: C
authors.initials: C
authors.lastname: Moller
authors.forename: R W
authors.initials: RW
authors.lastname: Pero
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000493:pharmacokinetics*; D002490:Central Nervous System / Q000187:drug effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D008875:Middle Aged
chemical_list: D000932:Antiemetics; D008787:Metoclopramide